Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.

ABSTRACT:

Background

Here, we aimed to assess the association of ALK variants and alterations with ensartinib response duration in NSCLC, and explore the potential value of computed tomography (CT) radiomic features in predicting progression-free survival (PFS).

Methods

We enrolled 88 patients with identified ALK variant NSCLC in a multicenter phase 2 trial, and assessed the impact of ALK variants and secondary ALK alterations on the clinical outcome (response duration) of patients receiving ensartinib. We also established a multifactorial model of clinicopathological and quantitative CT radiomic features to predict PFS and risk stratification. Kaplan-Meier analysis was conducted to identify risk factors for tumor progression.

Results

Univariate analysis indicated a statistical

SUBMITTER: Hou D 

PROVIDER: S-EPMC8410530 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature